whitepaper
Whitepaper: In search of a disease-modifying agent for Parkinson’s disease: a discovery story
Are selective, brain-penetrant inhibitors of LRRK2 an answer?
List view / Grid view
Drug Discovery
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
news
Exclusive speaker interview with Professor Nagy Habib – MiNA Therapeutics/Imperial College London
SMi are delighted to have, Nagy Habib, Head of HPB Surgery, Imperial College London and Co-Founder, MiNA Therapeutics, as the Keynote Address for day 1 at RNA Therapeutics 2018!
news
Charles River Laboratories presents newly expanded capabilities at Neuroscience 2017
Charles River Laboratories International, Inc. announced that its team of neuroscience drug discovery experts is presenting 27 scientific posters, both independently and collaboratively with clients, at Neuroscience 2017, the 47th annual meeting of the Society for Neuroscience (SfN).
news
Charles River announces expansion of in vitro oncology services
Partnership with InSphero provides additional 3D solutions...
news
Declines in plasticity reveal promising targets for Alzheimer’s disease
Brain changes linked to memory loss may provide a new focus for exploring ways to treat or prevent dementia...
news
Scientists develop broad-spectrum inhibitors of influenza virus
Scientists have developed broad-spectrum inhibitors of the influenza virus using artificial peptide molecules...
webinar
Integrated drug discovery panel – your questions answered!
28 September 2017 | By Charles River
During this peer panel discussion, team members from Charles River discussed their views and strategies on Drug Discovery...
news
Novartis and UC Berkeley collaborate to tackle ‘undruggable’ disease targets
Collaboration aims to unlock difficult drug targets and accelerate the discovery of new medicines in areas such as infectious diseases and cancer...
news
Parkinson’s UK Drug Discovery Manager joins DTR advisory board
Drug Target Review welcomes Janusz Kulagowski to its advisory board ...
news
Potential therapeutic protein inhibitors for Chagas disease
Researchers have used a multi-modal integrated approach to develop potential new anti-Chagas therapies...
whitepaper
Application note: Application of MultiCyt QBeads for high throughput cytokine profiling in human peripheral blood mononuclear cells
In this application note IntelliCyt Corporation report on the development and validation of their family of MultiCyt QBeads for the detection of cytokines in a high-throughput screening application on the iQue Screener...
article
Structure based drug discovery facilitated by crystallography
Drugs exert therapeutically meaningful effects if they bind with appropriate selectively and potency to their respective targets. Although many of the assay techniques employed in early-stage drug discovery provide evidence that a drug is acting upon the target under investigation, this is often indirect and the site of action and…
article
Expert view: A technological breakthrough in flow cytometry
Flow cytometry has become a widely used technology in life science research. It is also essential for many pharma and biotechnology companies due to its proficiency in identifying biomarkers, developing biopharmaceuticals, and assessing the efficiency of new pharmacological protocols...
article
Expert view: Single-cell sequencing in basic research and clinical applications
Next-generation sequencing (NGS) has greatly increased our understanding of biological phenomena and human disease. In particular, single-cell sequencing is one of the fastest-growing applications...
news
NIH awards $15m to support development of 3-D human tissue models
The NIH has announced 13 two-year awards totalling $15m, to develop 3-D microphysiological system platforms that model human disease...
